This is evident by the observations that EGFR inhibition led to less podocyte loss in models of diabetic nephropathy while podocyte-specific deletion of EGFR attenuated albuminuria and podocyte loss induced by hyperglycemia (Taniguchi et al., 2013; Li et al., 2018). Here, EGFR is linked to Hyperglycemia.